Dr. Bidard on the Importance of Elacestrant in ER+/HER2- Breast Cancer

Francois-Clement Bidard, MD, PhD, a professor in the Department of Medical Oncology, and the head of the Translational Research Group at the Institut Curie, discusses the importance of elacestrant (RAD-1901) in estrogen receptor (ER)–positive, HER2-negative, advanced or metastatic breast cancer.

The phase 3 EMERALD trial (NCT03778931) compared the efficacy and safety of elacestrant with a standard-of-care regimen of fulvestrant (Faslodex) or an aromatase inhibitor in patients with ER-positive, HER2-negative breast cancer that had advanced on endocrine therapy.

Based on positive data from the trial, a new drug application has been submitted to the FDA seeking the approval of elacestrant for the treatment of this population.

Elacestrant has performed better than other agents, which is a benefit for these patients, Bidard says. The agent must be used in the correct patient population to have the benefit translate to clinical practice, Bidard explains. Patients who could benefit include those who have not received any prior chemotherapy or those who harbor ESR1 mutations, Bidard adds.

Other methods should also be explored to stratify patients and understand which patients could be safely treated with single-agent elacestrant, Bidard concludes.